Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
暂无分享,去创建一个
T. Choueiri | M. Michaelson | T. Olencki | M. Morris | E. Small | D. Feldman | S. Dakhil | J. Picus | D. George | S. Halabi | B. Sanford | O. Hahn | Meghara Walsh